Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial.
Allogeneic hematopoietic stem cell transplantation
Extracorporeal photopheresis
Graft-versus-host disease
T regulatory cells
Journal
Experimental hematology & oncology
ISSN: 2162-3619
Titre abrégé: Exp Hematol Oncol
Pays: England
ID NLM: 101590676
Informations de publication
Date de publication:
16 Feb 2021
16 Feb 2021
Historique:
received:
21
12
2020
accepted:
09
02
2021
entrez:
17
2
2021
pubmed:
18
2
2021
medline:
18
2
2021
Statut:
epublish
Résumé
The aim of the present study was to evaluate the circulating T regulatory cells (Tregs) in patients undergoing extracorporeal photopheresis (ECP) for the prevention of chronic graft-versus-host disease (GvHD) and to search for any correlation between Tregs counts and chronic GvHD occurrence. Among n = 12 patients with complete longitudinal data, the median cumulative values of absolute peripheral Tregs counts were 21.64 and 63.49 cells/µL for patients who developed chronic GvHD and those who did not develop it, respectively (p = 0.05). The analysis of the median absolute counts of peripheral HLA-DR + Tregs provided similar results, showing that 20% (1 out of 5) and 100% (7 out of 7) of patients with HLA-DR + Tregs values of > 5 cells/µL were in the GvHD and non-GvHD groups, respectively (p = 0.01). In conclusion, the present results support the involvement of Tregs in the prevention of chronic GvHD in patients receiving ECP and suggest Tregs count as a potential biomarker of ECP effectiveness. Future strategies are needed to enhance Tregs expansion and/or activity in conjunction with ECP for an effective chronic GvHD prevention.
Identifiants
pubmed: 33593442
doi: 10.1186/s40164-021-00210-9
pii: 10.1186/s40164-021-00210-9
pmc: PMC7887801
doi:
Types de publication
Letter
Langues
eng
Pagination
14Commentaires et corrections
Type : ErratumIn
Références
Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055–66.
doi: 10.1056/NEJMoa1108188
Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT, et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia. 2015;29:396–405.
doi: 10.1038/leu.2014.180
Pierelli L, Bosi A, Olivieri A. “Best practice” for extracorporeal photopheresis in acute and chronic graft-versus-host disease by Societa’ Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers. Transfusion. 2018;58:217–22.
doi: 10.1111/trf.14400
Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation. 2007;84:31–9.
doi: 10.1097/01.tp.0000267785.52567.9c
Di Biaso I, Di Maio L, Bugarin C, Gaipa G, Dander E, Balduzzi A, et al. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation. 2009;87:1422–5.
doi: 10.1097/TP.0b013e3181a27a5d
Gandelman JS, Song DJ, Chen H, Engelhardt BG, Chen YB, Clark WB, et al. A Prospective Trial of Extracorporeal Photopheresis for Chronic Graft-versus-Host Disease Reveals Significant Disease Response and No Association with Frequency of Regulatory T Cells. Biol Blood Marrow Transplant. 2018;24:2373–80.
doi: 10.1016/j.bbmt.2018.06.035
Belizaire R, Kim HT, Poryanda SJ, Mirkovic NV, Hipolito E, Savage WJ, et al. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019;3:969–79.
doi: 10.1182/bloodadvances.2018029124
Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127:646–57.
doi: 10.1182/blood-2015-10-672345
Scottà C, Fanelli G, Hoong SJ, Romano M, Lamperti EN, Sukthankar M, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. 2016;101:91–100.
doi: 10.3324/haematol.2015.128934
Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood. 2002;100:941–7.
doi: 10.1182/blood-2002-01-0068
Machado LS, Roncon S, Pinho AC, Bordalo F, Antunes L, Campilho F, et al. Should we use extracorporeal photopheresis more often? Evidence from graft-versus-host disease patients monitored with Treg as a biomarker. Future Sci. 2020;6(8): 623.
Michallet M, Sobh M, Garban F, Bulabois CE, Yakoub-Agha I, Coiteux V, et al. Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study. Leuk Lymphoma. 2018;59:372–80.
doi: 10.1080/10428194.2017.1334120